Daniell Richard 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
TEVA EVP Daniell Richard Sells ~91,345 Shares
What Happened
- Daniell Richard, EVP, Europe Commercial at Teva (TEVA), sold a total of 91,345 shares in open‑market transactions on March 4, 2026, generating approximately $2.98 million in proceeds. The sales were executed at weighted‑average prices reported in the filing (individual sales at $32.46 and $32.95; price ranges reported $32.095–$33.30 and $32.905–$33.07).
- The filing also shows conversion/exercise entries for vested derivative awards (restricted share units) and a new grant: a 33,424‑share RSU award was recorded on March 4, 2026. Footnotes indicate the insider sold vested RSUs (including shares sold to cover tax withholding).
Key Details
- Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (no late filing indicated).
- Sales: 33,512 shares @ weighted avg $32.46 (proceeds $1,087,950); 20,461 shares @ weighted avg $32.46 (proceeds $664,256); 37,372 shares @ weighted avg $32.95 (proceeds $1,231,310). Total proceeds ≈ $2,983,516.
- Other entries: exercise/conversion (derivative) entries for 33,512 and 20,461 shares (conversion price reported as $0 in the filing — indicates conversion of RSUs to shares, not a cash purchase) and a grant (A) of 33,424 RSUs on March 4, 2026.
- Notable footnotes: trades were effected under a Rule 10b5‑1 trading plan adopted Nov 10, 2025 (F3); the insider sold vested RSUs including shares to cover tax withholding (F4); weighted‑average prices cover multiple sale lots with price ranges disclosed (F5, F6).
- Shares owned after the transactions are not shown in the excerpt provided.
Context
- The filing shows a common pattern where vested RSUs are converted to shares (derivative exercise/conversion) and then sold, including portions sold to cover taxes. The $0.00 price entries reflect conversion of RSUs rather than a cash purchase price.
- Sales by executives can be routine (compensation vesting, tax withholding, or pre‑planned 10b5‑1 sales) and do not necessarily indicate a change in personal view of the company. Purchases generally carry clearer bullish signals than routine sales.
Insider Transaction Report
Form 4
Daniell Richard
EVP, Europe Commercial
Transactions
- Exercise/Conversion
Ordinary Shares
[F1][F2]2026-03-04+33,512→ 156,639 total - Sale
Ordinary Shares
[F1][F3][F4][F5]2026-03-04$32.46/sh−33,512$1,087,950→ 123,127 total - Exercise/Conversion
Ordinary Shares
[F1][F2]2026-03-04+20,461→ 143,588 total - Sale
Ordinary Shares
[F1][F3][F4][F5]2026-03-04$32.46/sh−20,461$664,256→ 123,127 total - Sale
Ordinary Shares
[F1][F3][F6]2026-03-04$32.95/sh−37,372$1,231,310→ 85,755 total - Exercise/Conversion
Restricted Share Units
[F2][F7][F1]2026-03-04−33,512→ 0 total→ Ordinary Shares (33,512 underlying) - Exercise/Conversion
Restricted Share Units
[F2][F8][F1]2026-03-04−20,461→ 40,923 total→ Ordinary Shares (20,461 underlying) - Award
Restricted Share Units
[F2][F9][F1]2026-03-04+33,424→ 33,424 total→ Ordinary Shares (33,424 underlying)
Footnotes (9)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
- [F4]Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.905 to $33.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F7]Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.
- [F8]Restricted share units were granted on March 4, 2024, with 20,461 vested on each of March 4, 2025 and March 4, 2026, 20,461 vesting on March 4, 2027, and 20,462 vesting on March 4, 2028.
- [F9]Restricted share units were granted on March 4, 2026, with 8,356 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.
Signature
/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell|2026-03-06